ANCOR Platinum Partner Greenwich Biosciences (now Jazz Pharmaceuticals) has developed EPIDIOLEX, the first and only FDA approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).
During this webinar you’ll hear from Greenwich Biosciences and Nanette Wrobel, a registered pharmacist from ANCOR Gold Partner Tarrytown Expocare Pharmacy. They will discuss the latest updates regarding EPIDIOLEX, cannabinoid science, results from randomized clinical trials, plus labeling information.
Register to join Greenwich Biosciences for this webinar, Thursday, December 9 at 1 pm EST.
Stay Informed on the Latest Research & Analysis from ANCOR